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OBJECTIVES:
 
 To review the European systems currently
in place for the allocation of primary health-care budgets,
and to assess which model’s characteristics are likely to be
the most appropriate for adaptation to the Catalan region.
METHODS: Information was obtained from bibliographic
searches and personal communication with key European
budget holders. The following countries were considered
in the analysis: Finland; France; Germany; The Nether-
lands; Spain; Sweden; the UK (England and Scotland).
RESULTS: There were mainly three groups of variables
considered to capture the health-care needs of the popu-
lation: Age/sex—all countries/regions looked at the age of
patients, and only one of them did not look at the sex of
patients; Morbidity/mortality—most countries, measured
the health status of their patient population. The most
common variables to capture morbidity were: percentage
of chronic patients, standardized mortality, and mortality
of those younger than 65. Socioeconomic factors: all
countries/regions that had difficult access to a part of
their territory (i.e. Finland, Sweden and Scotland) in-
cluded a remoteness factor in their equations and pro-
vided those remote areas with more resources. Other
variables (e.g. unemployment rates, number of pension-
ers in one household, patient’s income, etc.) were also
considered in some countries.
CONCLUSIONS: In developing an effective tool for cal-
culating primary health-care budgets for Catalonia, it is
key to reflect the health-care needs of the population. The
age/sex of patients are widely recognized as the most ob-
vious variables to explain health-care expenditure. Al-
though it is also important to measure morbidity and the
socioeconomic circumstances of patients, the choice of
the most appropriate variables to capture such factors is
likely to vary significantly from one country to another.
Thus, a detailed statistical analysis will be required to
succeed in developing the final equation for the Catalan
region.
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BARRIERS THAT PREVENT THE USE OF 
ECONOMIC EVALUATIONS IN HOSPITAL 
FORMULARY DECISION-MAKING
Späth HM, Charavel M, Morelle M, Carrère MO
GRESAC - UMR 5823 du CNRS, Lyon, France
OBJECTIVE: Over the last 15 years pharmacoeconomics
research has grown rapidly, but economic evaluations
seem to have little impact on decision-making. We con-
ducted semi-structured interviews with hospital pharma-
cists in a French region to determine the barriers that pre-
vent their use in hospital formulary decision-making.
METHODS: We developed an interview schedule based
on a literature review and three pilot interviews. We in-
terviewed pharmacists in short stay hospitals with more
than 100 beds. Thirteen public hospitals (PH) and six pri-
vate clinics (PC) in the Rhone-Alpes region in France
were selected at random. Interview transcripts were
coded independently by two researchers. We compared
the six PC, financed on a fee-for-service basis, with the
13 PH, financed on a global budget basis, by multiple
correspondence analysis.
RESULTS: In all hospitals, economic evaluations have lit-
tle impact on formulary decision-making. The barriers that
prevent their use are: (1) decision-makers do not have
enough time to search and analyze them (all hospitals); (2)
published evaluations do not apply to their setting (all hos-
pitals); (3) decision-makers have no expertise in appraising
evaluations (5 PC and 8 PH); (4) budgets of different hos-
pital units are closed, and costs avoided by the inclusion
of a drug cannot be shifted to the pharmacy budget (3 PC
and 10 PH); (5) practitioners are reluctant not to give a
therapy for cost reasons (2 PC and 7 PH). The last two
barriers seem to have more impact in PH than in PC.
CONCLUSION: There are many barriers that prevent the
use of economic evaluations in hospital formulary decision-
making. The barriers related to the decision-making con-
text seem to be very important, especially in PH, financed
on a global budget basis. More research is needed to de-
termine the decision-makers’ needs for cost-effectiveness
information and the incentives to take it into account.
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OBJECTIVE: Cost-effectiveness of safety measures in
blood transfusion is not yet widely researched by phar-
macoeconomic investigators. Only a few studies have
been conducted, primarily in the US. Our objective is to
review the literature on cost-effectiveness of interventions
that enhance the safety of allogeneic (i.e. non-autologous)
transfusion of whole blood and blood products. This re-
view forms the basis for a European cost-effectiveness
model for new technologies in transfusion safety.
METHODS: We searched MEDLINE from 1990 on-
wards using the following search terms: “transfusion” in
combination with “costs” or “cost-effectiveness”. All
cost-effectiveness analyses in the English language that
use QALY’s or life-years gained as primary health out-
comes were included.
